Clinical trials: 5-Fluorouracil
Metastatic Colorectal Cancer
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
- Trial name
- CANTOR (NCT06792695)
- Testing
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 82 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral…
- Trial name
- KANDLELIT-001 (NCT05067283)
- Testing
- Calderasib, Pembrolizumab, carboplatin
- Where
- 75 sites in United States, Argentina and 19 more
- Volunteers
- 830 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer
This is a double-blind, randomized, multi-center, II/III study in at least 606 patients with advanced colorectal cancer. The study is being conducted to evaluate the safety of HR070803 combined with oxaliplatin, 5-FU/LV and…
- Trial name
- NCT05945901
- Testing
- HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
- Where
- China
- Volunteers
- 669 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Neoplasms
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
The main aim of this study is to check if people with advanced solid tumors have side effects from dazostinag, and to check how much dazostinag they can receive without getting significant side effects from it when given alone…
- Trial name
- iintune-1 (NCT04420884)
- Testing
- Dazostinag, Pembrolizumab, Platinum
- Where
- 62 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Takeda
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with…
- Conditions
- Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
- Trial name
- NCT04083599
- Testing
- GEN1042, Pembrolizumab, Cisplatin
- Where
- 76 sites in United States, Denmark and 10 more
- Volunteers
- 350 people
- Sponsor
- Genmab
Colorectal Cancer
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
This open-label, single arm, multicenter study evaluated the resection rate in participants with colorectal cancer and previously untreated unresectable liver-only metastases after adding bevacizumab to 5-FU based doublet…
- Trial name
- NCT01695772
- Testing
- 5-FU based doublet chemotherapy, bevacizumab
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer, Gastric Adenocarcinoma
A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
- Trial name
- DisTinGuish (NCT04363801)
- Testing
- DKN-01 300mg, DKN-01 600mg, DKN-01 400mg
- Where
- 48 sites in United States, Germany and 1 more
- Volunteers
- 247 people
- Sponsor
- Leap Therapeutics, Inc.
Advanced Solid Tumours
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with…
- Trial name
- NCT03421353
- Testing
- AZD9150, Durvalumab, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with metastatic or unresectable TNBC who have progressed on or after anthracycline-based chemotherapy or who have…
- Trial name
- NCT03175666
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
The purpose of this Chinese extension study is to evaluate efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as first-line treatment in…
- Trial name
- NCT03881111
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 20 sites in China
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Colorectal Cancer (mCRC)
A Clinical Study of Arfolitixorin in Patients With mCRC
This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.
- Trial name
- NCT06922383
- Testing
- Arfolitixorin, Leucovorin
- Where
- 3 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Isofol Medical AB
Colorectal Cancer
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and…
- Trial name
- NCT01478594
- Testing
- Tivozanib, Bevacizumab, mFOLFOX6
- Where
- 73 sites in United States, Australia and 10 more
- Volunteers
- 265 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Gastric Cancer
Phase II Study of ABI-007 for Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease…
- Trial name
- NCT00661167
- Testing
- ABI-007
- Where
- 10 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens.
- Trial name
- NCT06509906
- Testing
- M9466, Irinotecan, Folinic acid
- Where
- 12 sites in United States, Australia and 3 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Gastro-Intestinal Cancer
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.
- Trial name
- NCT01046864
- Testing
- 5-FU, Leucovorin, Irinotecan
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly used in cancer patients.
- Trial name
- NCT00110721
- Testing
- GM-CT-01 plus 5-Fluorouracil
- Where
- 6 sites in United States, Israel
- Volunteers
- 20 people
- Sponsor
- Galectin Therapeutics Inc.
Unresectable Metastatic Colorectal Cancer
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by…
- Trial name
- NCT04991948
- Testing
- CYAD-101, FOLFOX, Pembrolizumab
- Where
- 5 sites in United States, Belgium
- Volunteers
- 34 people
- Sponsor
- Celyad Oncology SA
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche